搜索到123篇“ IIB/IIIA“的相关文章
Predictors of disease recurrence after radical resection and adjuvant chemotherapy in patients with stage IIb-IIIa squamous cell lung cancer:A retrospective analysis
2024年
BACKGROUND Lung cancer(LC)is a global medical,social and economic problem and is one of the most common cancers and the leading cause of mortality from malignant neoplasms.LC is characterized by an aggressive course,and in the presence of disease recurrence risk factors,patients,even at an early stage,may be indicated for adjuvant therapy to improve survival.However,combined treatment does not always guarantee a favorable prognosis.In this regard,establishing predictors of LC recurrence is highly important both for determining the optimal treatment plan for the patients and for evaluating its effectiveness.AIM To establish predictors of disease recurrence after radical resection and adjuvant chemotherapy in patients with stage IIb-IIIa lung squamous cell carcinoma(LSCC).METHODS A retrospective case-control cohort study included 69 patients with LSCC who underwent radical surgery at the Orenburg Regional Clinical Oncology Center from 2009 to 2018.Postoperatively,all patients received adjuvant chemotherapy.Histological samples of the resected lung were stained with Mayer's hematoxylin and eosin and examined under a light microscope.Univariate and multivariate analyses were used to identify predictors associated with the risk of disease recurrence.Receiver operating characteristic curves were constructed to discriminate between patients with a high risk of disease recurrence and those with a low risk of disease recurrence.Survival was analyzed using the Kaplan-Meier method.The log-rank test was used to compare survival curves between patient subgroups.Differences were considered to be significant at P<0.05.RESULTS The following predictors of a high risk of disease recurrence in patients with stage IIb-IIa LSCC were established:a low degree of tumor differentiation[odds ratio(OR)=7.94,95%CI=1.08-135.81,P=0.049];metastases in regional lymph nodes(OR=5.67,95%CI=1.09-36.54,P=0.048);the presence of loose,fine-fiber connective tissue in the tumor stroma(OR=21.70,95%CI=4.27-110.38,P=0.0002);and fragmentation of the tumor s
Marina A SenchukovaEvgeniy A KalininNadezhda N Volchenko
血小板GP IIb/IIIa受体抑制率的免疫层析检测试剂盒和制备方法及检测方法
本发明涉及免疫层析检测领域,具体涉及一种血小板GP IIb/IIIa受体抑制率的免疫层析检测试剂盒和制备方法及检测方法,包括:所述试纸条A和样本稀释液中:所述样本稀释液、样品垫和/或结合垫上包含有荧光标记的血小板表面特异...
聂延召李奎胡飞张静邱笑违
胸腔镜肺叶切除术治疗老年IIb-IIIa期非小细胞肺癌的效果观察
2023年
目的:观察胸腔镜肺叶切除术治疗老年IIb-IIIa期非小细胞肺癌的效果。方法:选取张家港市第一人民医院2018年10月—2022年10月收治老年IIB-IIIa期非小细胞肺癌患者共91例,根据医生推荐及患者意愿分为对照组(n=40)与试验组(n=51)。其中对照组接受开胸手术治疗,试验组接受胸腔镜肺叶切除术治疗;比较两组手术时间、术中出血量、住院时间、术后24h VAS(视觉模拟评分法)评分、术后并发症发生率、手术前后白细胞介素6、肿瘤坏死因子α、C反应蛋白及生活质量综合评定问卷评分。结果:试验组手术时间、术中出血量、住院时间、术后24h VAS评分及术后并发症发生率均优于对照组,差异有统计学意义(P<0.05)。试验组术后24h白细胞介素6、肿瘤坏死因子α及C反应蛋白水平均低于对照组,差异有统计学意义(P<0.05);试验组术后12周心理功能、躯体功能、社会功能以及物质状态评分高于对照组,差异有统计学意义(P<0.05)。结论:胸腔镜肺叶切除术治疗老年IIb-IIIa期非小细胞肺癌可有效降低手术创伤,缩短康复用时,缓解疼痛症状,预防术后并发症,抑制炎症反应,并有助于改善日常生活质量。
王君陆亚东孙健飞施臻
关键词:胸腔镜肺叶切除术老年非小细胞肺癌
一种人源化抗人GP IIb/IIIa受体单克隆抗体Fab片段及其应用
本发明涉及一种人源化抗人GP IIb/IIIa受体单克隆抗体Fab片段,其由小鼠抗人GP IIb/IIIa受体单克隆抗体7E3的重链和轻链CDR区与人源IgG抗体Fab片段的框架所组成;通过将编码hGPba的核苷酸序列经...
张慧君杜勇陈太标
Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis被引量:3
2017年
Background Suboptimal myocardial reperfusion is common in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Furthermore, it results in increased infarct size and mortality rates. We performed a meta-analysis to evaluate the role of aspiration thrombectomy (AT) combined with intracoronary administration of glycoprotein IIb/IIIa inhibitors (GPI) in the improvement of myocardial reperfusion and clinical outcomes. Methods PubMed, Embase, Web of Science, and CENTRAL databases were searched for randomized controlled trials (RCTs) investigating combined AT and intracoronary GPI treatment versus AT alone. Outcomes of interest were thrombolysis in myocardial infarction myocardial perfusion grade (TMPG), infarct size (IS) assessed by cardiac magnetic resonance imaging, left ventricular ejection fraction (LVEF), major adverse cardiac events (MACE) at short-term (〈 1 month) and long-term (6-12 months) follow-up, and bleeding complications during the hospital stay. Results Eight trials involving 923 patients were included. Compared with AT alone, combined AT and intracoronary GPI significantly increased TMPG 3 flow (RR: 1.15, 95% CI: 1.04 to 1.26), reduced IS [mean difference (MD): -3.46, 95% CI: -5.18 to -1.73], and improved LVEF (MD: 1.44, 95% CI: 0.54 to 2.33). Furthermore, GPI use decreased the risk of MACE at long-term follow-up (RR: 0.60, 95% CI: 0.37 to 0.98). There was no significant difference between the two groups in the incidence of minor and major bleeding complications. Conclusions Our findings showed that compared with AT alone, combined AT and intracoronary GPI treatment resulted in improved myocardial reperfusion, better cardiac function, and MACE-free survival benefits at the long-term follow-up for patients with STEMI undergoing PPCI.
Xiao-Wei NIUJing-Jing ZHANGMing BAIYu PENGZheng ZHANG
关键词:META-ANALYSISTHROMBECTOMY
Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban被引量:6
2016年
Background: In worldwide, the mortality rate of acute myocardial infarction(AMI) raises year by year. Although the applications of percutaneous coronary intervention(PCI) and anticoagulants effectively reduce the mortality of patients with acute coronary syndrome(ACS), but also increase the incidence of bleeding. Therefore, drugs with stable anticoagulant effects are urgently required.Methods: We enrolled 894 patients with acute coronary syndrome who underwent percutaneous coronary intervention in Shenyang Northern Hospital from February 2010 to May 2012; 430 patients were included in the fondaparinux group(2.5mg/d), and 464 were included in the enoxaparin group(1mg/kg twice daily). Fondaparinux and enoxaparin were applied for 3–7 days. All patients were treated with tirofiban [10μg/kg for 3min initially and 0.15μg/(kg·min) for 1 to 3 days thereafter]. The primary efficacy endpoint was the incidence of a major adverse cerebrovascular or cardiovascular event. The primary safety endpoint was bleeding within 30 days and 1 year after percutaneous coronary intervention.Results: One-year data were available for 422 patients in the fondaparinux group and for 453 in the enoxaparin group. The incidence of a major adverse cerebrovascular or cardiovascular event(10.9% vs 12.6%, P=0.433) and cardiac mortality(0.5% vs 1.5%, P=0.116) were generally lower in the fondaparinux group than in the enoxaparin group, although the differences were not significant. Compared with the enoxaparin group, the fondaparinux group had a significantly decreased rate of bleeding at 30 days(0.9% vs 2.9%, P=0.040) and 1 year(2.4% vs 5.5%, P=0.018). In addition, the rate of major bleeding events was lower in the fondaparinux group, but this difference was not significant(0.2% vs 0.9%, 0.2% vs 1.1%).Conclusion: In tirofiban-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention, fondaparinux presented similar efficacy for ischemia events as enoxaparin. However, fondaparinux significantly decreased the inciden
Xin ZhaoXiao-Xu YangSu-Zhen JiXiao-Zeng WangLi WangChong-Huai GuLi-Li RenYa-Ling Han
关键词:FONDAPARINUXENOXAPARINANTICOAGULATION
用于结合血小板特异性糖蛋白IIB/IIIA的金属螯合物
本发明涉及与糖蛋白IIb/IIIa结合并可用于血栓的诊断成像,特别是磁共振成像的化合物。所公开的化合物能够与糖蛋白IIb/IIIa受体结合,兼具足够的成像灵敏度。
M.贝格尔J.洛尔克G.约斯特M.赖因哈特
文献传递
与血小板特异性糖蛋白IIb/IIIa结合的化合物以及其血栓成像的用途
本发明涉及新型的含氟化合物、其制备方法、其中间物的合成、其作为诊断试剂尤其用于血栓成像的试剂的用途。本发明涉及正电子发射层析成像(PET)试剂和其辅助前体试剂以及生产该用于在哺乳动物体内进行血栓成像的放射标记试剂的方法。...
马库斯·伯杰马丁·克鲁格尔杰西卡·勒尔克迈克尔·赖因哈特霍尔格·西贝内彻尔
文献传递
结合至血小板特异性糖蛋白IIb/IIIa的金属螯合化合物
本发明涉及结合至糖蛋白IIb/IIIa且可用于血栓的诊断成像(尤其是磁共振成像)的化合物。所公开的化合物使得能结合至糖蛋白IIb/IIIa受体合并适宜的弛豫率。
M.伯杰J.洛尔克G.约斯特M.莱因哈特
文献传递
冠脉介入治疗中冠脉内与静脉内应用GPⅡb/Ⅲa抑制剂疗效与安全性比较的Meta分析被引量:1
2014年
目的:系统评价急性冠脉综合征经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)中冠脉内应用GP IIb/III a抑制剂的疗效及安全性。方法:计算机检索Pubmed,Springer,Ovid,Embase,CochranceLibrary,Clinicahrails.gov和中国知网、万方数据库,检索从建库开始至2013年5月的所有相关临床随机对照研究。同时检索纳入文献的参考文献,并逐个进行质量评价和资料提取。统计学分析采用Rev-Man5.0软件。结果:共纳入15个RCT,共计4268例患者。Meta分析结果显示,与静脉内应用GPIIb/III a抑制剂相比,冠脉内应用GPIIb/IIIa抑制剂可以降低PCI术后主要不良心脏事件发生风险[OR=0.62,95%CI(0.49~0.77)]、再次心肌梗死发生风险[OR=0.63,95%CI(0.42,0.96)]、靶血管血运重建发生风险[OR=0.53,95%CI(0.35,0.82)];增加PCI术后达心肌梗死溶栓治疗(TIMI)3级血流的比率[OR=1.56,95%CI(1.14,2.14)]和TMP心肌灌注(TMP)达2~3级的比率[OR=2.14,95%CI(1.61,2.86)];增加术后2周心脏左室射血分数(LVEF)[OR=5.23,95%CI(1.76,8.70)]。但两组死亡风险之间的差异并没有统计学意义[OR=0.74,95%CI(0.53,1.03)]。安全性方面,冠脉内应用GPIIb/IIIa抑制剂并不增加严重出血[OR=1.15,95%CI(0.74,1.77)]及轻微出血[OR=0.94,95%CI(0.75,1.19)]的发生率。结论:现有的资料表明,冠脉内应用GPⅡb/III a抑制剂可以降低PCI术后主要不良心脏事件的发生风险,改善PCI术后心肌血流灌注,且不增加出血的风险。
徐兵陈梅顾永丽孙洁
关键词:META分析

相关作者

刘红
作品数:8被引量:3H指数:1
供职机构:河北医科大学
研究主题:干预预防 复发 中药联合 银屑病 顺铂
庞爱明
作品数:17被引量:51H指数:4
供职机构:苏州大学附属第一医院
研究主题:抗内皮细胞抗体 ITP SLE 表没食子儿茶素没食子酸酯 EGCG
王超
作品数:15被引量:49H指数:5
供职机构:北京大学药学院
研究主题:利尿剂 MS APCI 代谢 小分子药物
沈倍奋
作品数:606被引量:1,638H指数:17
供职机构:军事医学科学院基础医学研究所
研究主题:单克隆抗体 免疫毒素 IL-6 基因表达 白细胞介素6
赖春宁
作品数:73被引量:246H指数:7
供职机构:军事医学科学院基础医学研究所
研究主题:白血病 单克隆抗体 急性白血病 干细胞因子 基因表达